GET DAILY SIGNALSLantheus Holdings (LNTH) Delivers Mixed Q3 2026 Results Ahead of Curium Deal
Key Takeaways
- Worldwide revenue reached $389.9 million in Q3 2026, up 1.5% from $384.0 million a year earlier.
- GAAP diluted earnings per share fell 19.5% to $0.33, while adjusted diluted EPS rose 32.3% to $1.68.
- Neuraceq sales jumped 123.0% to $45.6 million, while flagship PYLARIFY slipped 0.7% to $238.9 million.
- The company suspended full-year 2026 guidance and skipped its earnings call because of its pending ~$8.0 billion all-cash merger with Curium.
- Cash and cash equivalents climbed to $683.6 million as of September 30, 2026, from $359.1 million at the start of the year.
Why This Quarter Matters for Investors
Lantheus Holdings, a radiopharmaceutical company focused on diagnostic imaging and targeted therapies, reported results for the third quarter ended September 30, 2026. The timing is notable because the firm has agreed to be acquired by Curium in an all-cash deal valued at up to roughly $8.0 billion. With the pending merger announced in August 2026 taking center stage, management suspended its full-year guidance and skipped the usual conference call. For investors, the numbers serve mainly as a check on whether the core business—anchored by PYLARIFY, DEFINITY, and Neuraceq—remains steady enough to support the transaction and any milestone-based payments.
Breaking Down the Reported Numbers
Lantheus posted third-quarter 2026 worldwide revenue of $389.9 million, a 1.5% increase from $384.0 million in the prior-year period. GAAP net income declined 19.4% to $22.4 million, and GAAP fully diluted earnings per share fell to $0.33 from $0.41. Adjusted (non-GAAP) diluted EPS rose 32.3% to $1.68, compared with $1.27 a year earlier, while adjusted net income increased 34.3% to $115.1 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Revenue growth varied across products. Neuraceq, the Alzheimer’s disease imaging agent, surged 123.0% to $45.6 million, and the cardiology ultrasound agent DEFINITY grew 4.8% to $85.7 million. PYLARIFY, the prostate cancer PET imaging agent, declined 0.7% to $238.9 million. GAAP operating income decreased 26.2% to $32.2 million amid higher research and development costs, while adjusted operating income climbed 28.1% to $153.2 million. The company generated $102.0 million in operating cash flow and $99.9 million in free cash flow during the quarter.
How the Market Is Responding
With the merger agreement in place, LNTH stock is now largely tied to the deal terms rather than quarterly fundamentals. Curium US Holdings LLC has agreed to acquire all outstanding shares for $102.50 per share in cash, plus non-transferable CVRs offering up to an additional $12.00 per share tied to commercial milestones through 2030. Near-term trading therefore tends to follow progress on regulatory and antitrust approvals more than earnings beats or misses. The U.S. Federal Trade Commission extended its review of the transaction in October 2026, underscoring that closing timing remains a key variable. The decision to forgo guidance and a conference call also removed some of the usual post-earnings catalysts.
What to Watch Going Forward
The dominant factor ahead is whether the Curium transaction closes as planned, with completion currently expected in the first half of 2027. Antitrust and foreign direct investment approvals are still outstanding, and any delay or shift in terms would directly affect shareholder value. On the operational side, several regulatory milestones could support longer-term growth. The company received FDA approval for TAUKLARIFY, an F-18-labeled tau PET imaging agent for Alzheimer’s assessment, and final FDA approval for BRAVNETSA, a lutetium-based treatment for certain neuroendocrine tumors. PYLARIFY TruVu also secured transitional pass-through payment status and a permanent reimbursement code effective October 1, 2026, supporting a phased commercial launch. I’m watching the pace of PYLARIFY TruVu adoption and continued Neuraceq momentum closely, along with any updates on the CVR milestones that could unlock additional per-share value.
Using AI Tools for Deeper Analysis
From what I see, tools like Tickeron’s AI Trend Prediction Engine can help put these results in broader context by comparing performance signals across the sector. I also reviewed the latest patterns with Tickeron’s AI Real Time Patterns to gauge any technical shifts around the earnings release.
Exploring Tickeron’s AI Screener
I find Tickeron’s AI Screener especially useful during earnings season because it lets me quickly filter stocks by industry, technical patterns, fundamentals, and AI-driven signals. In this case it helped confirm how LNTH stacks up against peers on key metrics without spending hours on manual screens. It is a practical way to surface ideas that align with specific investment criteria while keeping the focus on data rather than noise.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LNTH in upward trend: price rose above 50-day moving average on October 29, 2026
LNTH moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LNTH as a result. In 58 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for LNTH just turned positive on October 02, 2026. Looking at past instances where LNTH's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for LNTH crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +0.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNTH advanced for three days, in 260 of 329 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 248 of 291 cases where LNTH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LNTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
LNTH broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. LNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.013) is normal, around the industry mean (7.659). P/E Ratio (23.806) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.275) is also within normal values, averaging (181.047).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical imaging products
Industry PharmaceuticalsGeneric
Advertisement